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Chemoembolization is an important treatment for hepatocellular
carcinoma (HCC) and has been shown to improve survival com-
pared with best supportive care in two randomized controlled
trials [1,2]. It is also the current standard of care for intermediate
HCC as deﬁned by the Barcelona Clinic Liver Cancer (BCLC) stag-
ing system [3]. The commonly used method of ‘‘conventional’’
transcatheter arterial chemoembolization involves intra-arterial
infusion of lipiodol mixed with anticancer drugs such as doxoru-
bicin into the feeding artery of the HCC. However, as you are
probably aware, various techniques are used in chemoemboliza-
tion for HCC, but there is a lack of standardization across them
[4]. The method used for chemoembolization is different in East-
ern, including Korea, and Western countries, and the actual
details of the technique vary between interventional radiologists
in the same medical center as well as between medical centers in
the same country. Therefore, a physician may have difﬁculty in
predicting the therapeutic efﬁcacy of chemoembolization and
has a question about that such difference of technical details
could result in different outcomes. Combination of sorafenib with
chemoembolization might complement such pitfalls of
chemoembolization.
In chemoembolization, the gelfoam particles are generally
used as the embolic materials that are injected after sufﬁcient
infusion of lipiodol mixture into the feeding artery. This maxi-
mizes the embolic effect, blocks blood ﬂow into the tumor, and
impedes the washout of lipiodol. However, there is a risk of ische-
mia of the extratumoral liver tissue, resulting in biliary strictures,
bile duct cysts and, as known, VEGF surge. We consider that gel-
foam particle infusion increases the risk of ischemic complica-
tions, and, in our center, we have restricted their use in
chemoembolization to help achieve superselection of the feeding
artery. We use two different methods for chemoembolization in
daily practice. In cases where there are several small nodular type
HCC, we try to select the single feeding artery of each tumor, and
to achieve complete necrosis of the tumor we use aggressive
chemoembolization, referred to as ‘‘angiographic subsegmentec-
tomy’’ [5]. In other cases, we try to minimize normal liver paren-
chymal damage or ischemic complications by using
chemoembolization. The cases in our clinical study [6] included
multiple and/or large tumors, and therefore, the superselectionFondaparinux (Arixtra⁄) hepato
he Editor:
daparinux (Arixtra⁄) is a synthetic pentasaccharide, which
ctively binds to antithrombin (AT) and causes a rapid and
ctive inhibition of Factor Xa [1]. Fondaparinux is effective
reventing [1] and treating [2] venous thrombosis and has a
able place in the treatment of patients with acute coronary
drome [3]. Fondaparinux has been reported to be well toler-
Journal of Hepatology 2of multiple feeding arteries for chemoembolization could not be
achieved. If we had used gelfoam particles in these cases, the inci-
dence of ischemic complications might have increased and
administration of sorafenib would be more delayed.
We would not expect all chemoembolization treatments to
have maximal therapeutic effect because of the reasons described
above. Combined treatment with chemoembolization and sorafe-
nib may be an appropriate therapeutic option for these patients.toxicity in a 6 year-old child
ated and thrombocytopenia has only been reported as isolated
occurrences [4]. It does not undergo hepatic metabolism and
does not interact with liver function [5]. Liver toxicity induced
by fondaparinux has not yet been described. We report a case
of acute hepatitis likely related to fondaparinux administration
in a 5 year-old child who presented with a left-sided axillary
veno-lymphatic malformation diagnosed at 9 days of life.
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